Zurich Extends Cannabis Pilot Program to 2028

Zurich is not just continuing its experiment with legal cannabis; it is aggressively expanding it. In a decisive move announced this Monday, the City Council applied to extend the landmark "Züri-Can" pilot project through 2028, pushing well past the original 2026 deadline. This extension comes with a price tag of CHF 800,000 ($1 million), a figure the city views not as a cost, but as a critical investment in public health and urban order.

The message from the Limmat city is clear: regulation works. With over 2,300 participants already obtaining cannabis legally, the project has moved beyond a tentative trial to become a cornerstone of modern Zurich social policy. By committing to this two-year extension, authorities are signaling that the data gathered so far is too valuable to cut short. The city is effectively buying time to gather more robust evidence, ensuring that when the final verdict on Swiss cannabis legalization is written, it will be based on irrefutable, long-term data rather than short-term snapshots.

A staggering CHF 7.5 million has been ripped directly from the hands of illegal dealers. This is the financial reality of the "Züri-Can" project, which has successfully diverted a massive stream of revenue away from the criminal underworld and into a controlled, observable environment. The sheer volume of the shift is undeniable: consumers have purchased approximately 750 kilograms of cannabis across 88,000 individual sales transactions since the project's inception.

This is not merely a social experiment; it is an economic disruption. Every gram sold through the 21 regulated pharmacies and social clubs represents a loss for the black market, which thrives on lack of oversight and quality control. City Councillor Andreas Hauri emphasized that the project centers on protecting users from the inherent risks of the street trade—risks that include synthetic adulterants and unpredictable potency. By offering a safe, consistent alternative, Zurich is proving that consumers will choose a legal avenue when it is available, effectively starving the illicit market of its most reliable customers.

Science demands diversity, and Zurich is pivoting to ensure its data reflects the real world. While the pilot has been a success, the city acknowledges a demographic blind spot: the current participant base does not fully represent the broader population. To correct this, the federal government approved a capacity surge in July 2025, raising the participant cap from 2,100 to 3,000.

The goal is specific and urgent: attract more women and occasional users. These groups have been historically underrepresented in the study, skewing the data toward frequent, male users. By extending the timeline to 2028 and widening the net, the Psychiatric University Clinic Zurich—which supervises the study—can analyze the health impacts of regulated cannabis on a far more accurate cross-section of society. This is a critical adjustment. For the findings to shape national law, they must prove that regulation is safe and effective for everyone, not just the heavy user demographic.

Zurich is writing the playbook for the rest of Switzerland. As the economic hub of the nation, the city's ability to manage a long-term, large-scale distribution network without compromising public safety is the ultimate test case for federal legalization. The extension to 2028 suggests that the city is confident, but cautious—prioritizing a "health-first" approach over a free-for-all commercial market.

The implications extend far beyond the canton's borders. With other Swiss cities watching closely, the success of "Züri-Can" in balancing public health with consumer demand will likely dictate the pace of national reform. If Zurich can sustain these numbers—keeping millions out of the black market while maintaining strict health controls—it will be impossible for federal lawmakers to ignore the evidence. The extension is not just a delay of the conclusion; it is a solidification of the new normal.